A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants.

ABSTRACT: Milvexian is an oral factor XIa inhibitor in development for prevention of major thromboembolic conditions. This randomized, double-blind, placebo- and positive-controlled, multiple-dose, four-period crossover study assessed the cardic safety of milvexian (including effects on the QT interval of the electrocardiogram), with a supporting in vitro component. Sixty-six participants were enrolled. In each treatment period, participants received milvexian (100 or 200 mg) or placebo every 12 h for 4 days. A single-dose moxifloxacin (400 mg) served as a positive control. Electrocardiographs and time-matched pharmacokinetic samples were collected during each period. In mixed-effects models, the upper limit of the two-sided 90% confidence interval for the least squares means for change from baselin

SUBMITTER: Zannikos P 

PROVIDER: S-EPMC12813654 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature